Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

Sponsor

State University of New York - Upstate Medical University (Other)

Overall Status

Completed

CT.gov ID

NCT01738815

Collaborator

(none)

Enrollment

Location

Arm

Actual Duration (Months)

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.

Condition or Disease	Intervention/Treatment	Phase
Hematuria Bladder Cancer	Drug: Valproic Acid	Early Phase 1

Detailed Description

Bladder cancer is the fourth most common cancer in the United States with over 60,000 new cases each year. It can usually be treated initially by insertion of an endoscope into the bladder and surgically removing the tumor, a procedure known as cystoscopy and trans-urethral resection of bladder tumor (TURBT). For most patients this procedure will successfully remove all of the detectable tumor. Unfortunately over 40% of all patients will develop a cancer recurrence in less than two years and all patients remain at increased risk of recurrence for the remainder of their lives. This risk requires life long monitoring and this is best accomplished with regular cystoscopic examinations. The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth. Patients with suspected bladder cancer will be invited to participate in the study, if a tumor is observed during cystoscopy it will be sampled for research purposes and then according to standards of care, the patient scheduled for TURBT under general anesthesia. In the interval between discovery of a bladder tumor and resection, usually two to four weeks, the patient will be given valproic acid to take orally. In addition, tumors from patients with known or suspected bladder cancer referred for TURBT or cystectomy will be sampled. The tumor pieces obtained before and after taking valproic acid and from the referral patients not treated with valproic acid will be analyzed to see if the drug has changed what genes are active. We have found that valproic acid causes bladder cancer cells to make more of the protein, thrombospondin-1. This protein inhibits the growth of new blood vessels and so increased thrombospondin-1 in bladder tumors should inhibit their growth by decreasing the blood supply. Valproic acid may change thrombospondin-1 levels through inhibition of histone deacetylases. We will also assay HDAC activity in the tumor specimens. If valproic acid alters thrombospondin-1 levels and HDAC activity in bladder cancer patients further study to see if it can reduce growth will be justified. Valproic acid is a drug approved for the treatment of seizure disorders that is generally well tolerated with few side effects. It may prove useful in reducing bladder cancer recurrence and progression.

Study Design

Study Type:

Interventional

Actual Enrollment :

43 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

Actual Study Start Date :

Dec 1, 2011

Actual Primary Completion Date :

May 1, 2013

Actual Study Completion Date :

Apr 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: valproic acid Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection	Drug: Valproic Acid 500 mg orally, once daily for up to 30 days Other Names: Depakote ER

Arm

Intervention/Treatment

Experimental: valproic acid

Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection

Drug: Valproic Acid

500 mg orally, once daily for up to 30 days

Other Names:

Depakote ER

Outcome Measures

Primary Outcome Measures

Thrombospondin-1 gene expression [1 day]
Expression of thrombospondin-1 will be assayed using quantitative real-time PCR and western blotting. Comparisons will be intra-patient for paired specimens acquired prior to and after treatment and inter-patient for treated and un-treated patients.

Secondary Outcome Measures

Angiogenesis, proliferation, and histone deacetylase activity markers [1 day]
Histone deacetylase activity, angiogenesis, and proliferation markers will be assayed using qPCR and western blotting of tumor biopsy specimens. Comparisons will be intra-patient for paired specimens acquired prior to and after treatment and inter-patient for treated and un-treated patients.

Eligibility Criteria

Criteria

Ages Eligible for Study:

21 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient over the age of 21
Bladder tumor suspected or confirmed
ECOG status 0 to 2
Premedication Lab values:

Absolute Neutrophil Count >750 cells/m3 AST/ALT less than 1.5xN Amylase less than 1.5xN Platelet Count > 125,000 PT/PTT > 1.3xN Hemoglobin > 8gm/dL Creatinine less than 1.5xN

Exclusion Criteria:

Allergy to valproic acid
Concurrent chemotherapy
Pre-menopausal women
Active systemic infection (HepatitisB,C)
Coagulation disorders
Concurrent medication: Tolbutamide, Warfarin, Zidovudine, Benzodiazepine, Clonazepam, Diazepam, Any anti-convulsant therapy
Seizure disorder
Dementia
History of Pancreatitis
HIV diagnosis/treatment
Liver disease/dysfunction